Immunic Aktie [WKN DE: A2PHD4 / ISIN: US4525EP1011]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Immunic Inc Registered Shs

21.10.22		Pre-market Movers: IMUX, ARC, SNAP, VRE, JAN… (RTTNews)
20.10.22		Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate (PR Newswire)
17.10.22		Pre-market Movers: INPX, GEHI, HAPP, MPTI, ADEA… (RTTNews)
12.10.22		Pre-market Movers: SLS, CANG, HKD, GATO, CCJ… (RTTNews)
10.10.22		Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing (PR Newswire)
04.10.22		Immunic to Participate in Scientific and Industry Conferences in October (PR Newswire)
20.09.22		Immunic: Data Shows Favorable Pharmacokinetic Profile For IMU-856 In Single, 14-Day Multiple Dosing (RTTNews)
20.09.22		Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects (PR Newswire)
01.09.22		Immunic, Inc. to Participate in Investor Conferences in September (PR Newswire)
30.08.22		Immunic To Announce Celiac Trial Data Next Month (RTTNews)
16.08.22		Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regenera... (PR Newswire)
02.08.22		Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference (PR Newswire)
28.07.22		Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update (PR Newswire)
06.07.22		Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén (PR Newswire)
28.06.22		Immunic to Participate in Industry and Scientific Conferences in July (PR Newswire)
15.06.22		Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translation... (PR Newswire)
08.06.22		Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June (PR Newswire)
02.06.22		Immunic : Phase 2 Trial Of Vidofludimus Calcium On Ulcerative Colitis Fails To Meet Primary Goal (RTTNews)
02.06.22		Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update (PR Newswire)
05.05.22		Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease (PR Newswire)
03.05.22		Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update (PR Newswire)
25.04.22		Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences (PR Newswire)
16.03.22		Immunic Promotes Glenn Whaley To CFO (RTTNews)
16.03.22		Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer (PR Newswire)
08.03.22		Immunic, Inc. to Participate in Investor and Scientific Conferences in March (PR Newswire)
18.02.22		Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 C... (PR Newswire)
17.02.22		Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update (PR Newswire)
08.02.22		Immunic, Inc. to Participate in Investor and Scientific Conferences in February (PR Newswire)
02.02.22		Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor (PR Newswire)
14.12.21		Immunic's IMU-935 Demonstrates Favorable Safety Profile In Phase I Trial (RTTNews)
14.12.21		Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor (PR Newswire)
09.12.21		Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
23.11.21		Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference (PR Newswire)
18.11.21		Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis (PR Newswire)
01.11.21		Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update (PR Newswire)
28.10.21		Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis (PR Newswire)
27.10.21		Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935 (PR Newswire)
14.10.21		Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer (PR Newswire)
30.09.21		Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis (PR Newswire)
28.09.21		Immunic, Inc. to Participate in Scientific and Investor Conferences in October (PR Newswire)
22.09.21		Immunic, German University Sign License Deal To Treat Viral Infections; Terms Not Disclosed (RTTNews)
22.09.21		Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19 (PR Newswire)
08.09.21		Immunic, Inc. to Participate in Investor and Scientific Conferences in September (PR Newswire)
06.08.21		Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity (PR Newswire)
03.08.21		Immunic, Inc. to Participate in Investor Conferences in August (PR Newswire)
15.07.21		Pre-market Movers: ATHE, HUDI, VERB, SGOC, IMUX… (RTTNews)
12.07.21		Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist (PR Newswire)
01.07.21		Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis (PR Newswire)
28.06.21		Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July (PR Newswire)
10.06.21		Immunic, Inc. to Participate in Industry and Investor Conferences in June (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Support bei 180 US-Dollar hält! Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Bitcoin über 100.000 US-Dollar: Lohnt sich der Einstieg für Anleger jetzt noch?

RBI-Aktie tiefer: RBI droht Milliarden-Zahlung im Streit mit Russland

Banque Syz prognostiziert Überraschungen für 2025: Musk-Meloni-Hochzeit und das Ende der Musk-Trump-Verbindung

Crash oder Rally: Das sind die Experten-Prognosen für Kryptowährungen wie Bitcoin, Ethereum & Co. im Jahr 2025

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	23.12.2024 21:13
Kaufwert:	EUR
	Hinzufügen Speichern